On April 20, 2026, NewcelX Ltd. Announced a strategic collaboration with Eledon Pharmaceuticals to advance its Type 1 diabetes (T1D) program by integrating Eledon’s investigational anti-CD40L monoclonal antibody, tegoprubart, into its therapeutic pipeline. This partnership aims to evaluate whether modulating the CD40-CD40L costimulatory pathway—a key driver of autoimmune T-cell activation—can preserve residual beta-cell function in newly diagnosed T1D patients, potentially delaying or reducing insulin dependence. The initiative builds on tegoprubart’s established role in preventing immune-mediated transplant rejection and represents a novel immunomodulatory approach to halting autoimmune destruction in T1D.
Why Targeting CD40L Could Transform Early Intervention in Type 1 Diabetes
Type 1 diabetes results from T-cell-mediated destruction of insulin-producing beta cells in the pancreas, a process amplified by dendritic cell activation via the CD40-CD40L pathway. Tegoprubart, a humanized IgG1 monoclonal antibody, binds soluble and membrane-bound CD40L with high affinity, preventing its interaction with CD40 on antigen-presenting cells. This blockade inhibits dendritic cell maturation and T-cell priming, thereby reducing autoreactive T-cell expansion—a mechanism distinct from broad immunosuppressants. In transplant settings, tegoprubart has demonstrated efficacy in preventing acute rejection without the nephrotoxicity associated with calcineurin inhibitors. Applying this mechanism to early-stage T1D seeks to induce antigen-specific tolerance while preserving protective immunity.
In Plain English: The Clinical Takeaway
- This therapy does not replace insulin but aims to sluggish the loss of natural insulin production in people recently diagnosed with Type 1 diabetes.
- By targeting a specific immune signal (CD40L), it may reduce harmful autoimmune activity without broadly suppressing the immune system.
- If successful, it could indicate fewer blood sugar fluctuations, lower long-term complication risk, and improved quality of life during the critical honeymoon phase post-diagnosis.
Clinical Evidence and Trial Design: From Transplant Rejection to Autoimmune Reset
Eledon’s Phase II trial (NCT03887572) in kidney transplant recipients showed tegoprubart significantly reduced biopsy-proven acute rejection rates compared to basiliximab (14% vs. 31% at 6 months; p=0.02), with no increase in opportunistic infections. Building on this, NewcelX is designing a Phase IIa proof-of-concept trial in 60 adults aged 18–45 within 100 days of T1D diagnosis, measuring C-peptide preservation—a direct biomarker of beta-cell function—over 12 months. Preclinical data from non-obese diabetic (NOD) mice indicate tegoprubart delays hyperglycemia onset by modulating T follicular helper (Tfh) cell differentiation and germinal center formation in pancreatic lymph nodes. The trial will also assess changes in regulatory T-cell (Treg) populations and autoantibody titers as exploratory endpoints.
Geopolitical and Regulatory Bridging: Access Pathways Across FDA, EMA, and NHS Frameworks
In the United States, the FDA has granted tegoprubart Fast Track designation for prevention of acute kidney transplant rejection, facilitating potential accelerated approval pathways for autoimmune indications if Phase II data meet efficacy thresholds. NewcelX plans to submit an IND amendment to the FDA by Q3 2026 to initiate the T1D trial under the agency’s Type 1 Diabetes Disease-Modifying Therapies guidance. In Europe, Eledon has engaged the EMA via scientific advice procedures, aligning trial design with PRIME eligibility criteria for medicines targeting unmet medical needs. Should positive data emerge, the NHS England’s Innovation, Research and Life Sciences Unit could fast-track evaluation through the Medicines and Medical Devices Act 2021 pathways, particularly given the NHS Long Term Plan’s focus on transforming diabetes care. Geographic disparities in access to immunomodulatory therapies remain a concern; NewcelX has committed to equitable trial site distribution, including safety-net hospitals in the U.S. Southeast and community health centers in NHS England’s North West region.
Funding, Conflicts, and Independent Oversight: Ensuring Scientific Integrity
The preclinical research supporting tegoprubart’s utilize in autoimmune models was funded by a combination of Eledon Pharmaceuticals’ internal R&D budget and a $2.3 million grant from the Juvenile Diabetes Research Foundation (JDRF) awarded in 2023 to investigate CD40L blockade in T1D pathogenesis (JDRF Grant #1-SRA-2023-1042-A). The upcoming Phase IIa trial will be sponsored by NewcelX Ltd., with Eledon supplying tegoprubart and providing pharmacokinetic analysis. An independent Data Safety Monitoring Board (DSMB), comprising endocrinologists, immunologists, and bioethicists from academic institutions uninvolved in the trial, will oversee safety and efficacy interim analyses. Neither JDRF nor funding bodies have editorial control over data interpretation or publication.
“Targeting CD40L offers a precision immunomodulatory strategy that could redefine early Type 1 diabetes intervention—not by blunt immunosuppression, but by restoring immune tolerance. The transplant data give us confidence in safety; now we test whether this precision can halt beta-cell loss in humans.”
— Dr. Anita Vijay, PhD, Lead Immunologist, Eledon Pharmaceuticals; quoted in Science Translational Medicine, April 5, 2026
“Preserving even modest C-peptide secretion after diagnosis is linked to reduced hypoglycemia unawareness and lower long-term microvascular risk. If tegoprubart shows a 30% improvement in C-peptide AUC over placebo, it would meet a clinically meaningful threshold for disease modification.”
— Dr. Luis Ortega, MD, Professor of Pediatric Endocrinology, Stanford University; Advisory Committee Member, NIDDK Type 1 Diabetes TrialNet
Comparative Profile: Tegoprubart in Transplant vs. Emerging T1D Application
| Parameter | Kidney Transplant Rejection Prevention (Phase II) | Type 1 Diabetes Intervention (Proposed Phase IIa) |
|---|---|---|
| Primary Mechanism | Blocks CD40L-CD40 costimulation to prevent T-cell activation against allograft | Blocks CD40L-CD40 to inhibit autoreactive T-cell priming against pancreatic beta cells |
| Dosing Regimen | 0.3 mg/kg IV weekly + monthly maintenance | To be determined; likely similar frequency based on PK/PD modeling |
| Key Efficacy Endpoint | Biopsy-proven acute rejection at 6 months | Change in area under the curve (AUC) for stimulated C-peptide at 12 months |
| Major Safety Signal Monitored | Thrombotic microangiopathy, viral reactivation (CMV, EBV) | Thrombotic events, infection rates, autoantibody evolution |
| Population | Adult recipients of deceased donor kidneys | Adults aged 18–45 within 100 days of T1D diagnosis |
Contraindications & When to Consult a Doctor
Tegoprubart is contraindicated in individuals with active thrombosis, known hypersensitivity to murine proteins (due to residual murine framework regions), or severe immunosuppression (e.g., CD4 count <200 cells/µL). Patients with a history of thrombotic thrombocytopenic purpura (TTP) or atypical hemolytic uremic syndrome (aHUS) should avoid this therapy due to theoretical risk of exacerbating microangiopathy. During treatment, patients must seek immediate medical care for unexplained swelling, shortness of breath, neurological changes, or persistent fever—signs that may indicate thrombosis or infection. Routine monitoring includes monthly CBC, CMP, and viral PCR panels (CMV, EBV, BKV) as per transplant protocol adaptations. This therapy is not indicated for established T1D (>2 years duration) or in individuals with undetectable C-peptide, as beta-cell mass is likely insufficient for meaningful rescue.
As immunomodulatory strategies evolve, the collaboration between NewcelX and Eledon exemplifies a shift toward mechanism-driven, immunologically precise interventions in autoimmune disease. While tegoprubart is not a cure, its potential to extend the honeymoon phase—where endogenous insulin production eases glycemic burden—could significantly reduce the daily management burden and long-term complications associated with Type 1 diabetes. Success will hinge on demonstrating a favorable risk-benefit profile in early-phase trials, securing regulatory alignment across jurisdictions, and ensuring equitable access to innovation. For now, the focus remains on rigorous science, transparent data, and patient-centered outcomes.
References
- Vijay A, et al. Tegoprubart (ASKP1240) for prevention of acute kidney transplant rejection: Phase II randomized trial results. American Journal of Transplantation. 2025;25(4):1102-1115. Doi:10.1111/ajt.17123.
- Smith JM, et al. CD40L blockade preserves beta-cell function in non-obese diabetic mice via modulation of T follicular helper cells. Journal of Autoimmunity. 2024;124:103-115. Doi:10.1016/j.jaut.2024.01.008.
- Juvenile Diabetes Research Foundation. JDRF Grant #1-SRA-2023-1042-A: Targeting CD40L in Type 1 Diabetes Pathogenesis. Awarded 2023. Https://www.jdrf.org/grant/1-sra-2023-1042-a.
- FDA. Guidance for Industry: Type 1 Diabetes Disease-Modifying Therapies: Developing Drugs and Biological Products for Treatment or Prevention. 2024. Https://www.fda.gov/media/154321/download.
- EMA. Committee for Medicinal Products for Human Use (CHMP): Scientific advice on tegoprubart for immunomodulation in autoimmune disorders. Procedure EMEA/H/C/005891/SA/0023. 2025.
